RGLS Regulus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGLS

Price (delayed)

$2.78

Market cap

$181.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.58

Enterprise value

$160.55M

Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop ...

Highlights
RGLS's debt has dropped by 62% year-on-year and by 29% since the previous quarter
RGLS's EPS is up by 15% year-on-year
Regulus Therapeutics's equity has decreased by 36% YoY and by 25% from the previous quarter
Regulus Therapeutics's quick ratio has decreased by 25% from the previous quarter and by 17% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://regulusrx.com
Peers: ALNY BIIB AZN SGMO

Key stats

What are the main financial stats of RGLS
Market
Shares outstanding
65.47M
Market cap
$181.99M
Enterprise value
$160.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.65
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$29.43M
EBITDA
-$29.21M
Free cash flow
-$27.38M
Per share
EPS
-$1.58
Free cash flow per share
-$1.44
Book value per share
$1.05
Revenue per share
$0
TBVPS
$1.62
Balance sheet
Total assets
$30.75M
Total liabilities
$9.56M
Debt
$2.39M
Equity
$21.19M
Working capital
$19.67M
Liquidity
Debt to equity
0.11
Current ratio
3.31
Quick ratio
2.8
Net debt/EBITDA
0.73
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-80.6%
Return on equity
-109.2%
Return on invested capital
-893.2%
Return on capital employed
-132.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGLS stock price

How has the Regulus Therapeutics stock price performed over time
Intraday
-0.71%
1 week
4.12%
1 month
31.75%
1 year
133.61%
YTD
117.19%
QTD
-3.47%

Financial performance

How have Regulus Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.11M
Net income
-$30.04M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 10% year-on-year and by 4.6% since the previous quarter
Regulus Therapeutics's net income has decreased by 6% YoY and by 4.4% from the previous quarter

Growth

What is Regulus Therapeutics's growth rate over time

Valuation

What is Regulus Therapeutics stock price valuation
P/E
N/A
P/B
2.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RGLS's EPS is up by 15% year-on-year
The stock's price to book (P/B) is 194% more than its last 4 quarters average of 0.9 and 66% more than its 5-year quarterly average of 1.6
Regulus Therapeutics's equity has decreased by 36% YoY and by 25% from the previous quarter

Efficiency

How efficient is Regulus Therapeutics business performance
The ROIC has plunged by 134% from the previous quarter
Regulus Therapeutics's return on equity has shrunk by 59% YoY and by 16% QoQ
RGLS's return on assets has dropped by 52% year-on-year and by 16% since the previous quarter

Dividends

What is RGLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGLS.

Financial health

How did Regulus Therapeutics financials performed over time
Regulus Therapeutics's total assets has decreased by 34% YoY and by 19% QoQ
RGLS's total liabilities is down by 29% YoY
RGLS's debt is 89% smaller than its equity
RGLS's debt has dropped by 62% year-on-year and by 29% since the previous quarter
The debt to equity has contracted by 42% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.